Condition
Transthyretin Amyloidosis With Cardiomyopathy
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07358078RecruitingPrimary
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
NCT07052903Phase 3RecruitingPrimary
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Showing all 2 trials